Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
June 3, 2024—MedTech Breakthrough announced that Epredia has been selected as the winner of best new technology solution—pathology for its SlideMate Laser printer in the 8th annual MedTech Breakthrough Awards program.
May 29, 2024—The American Clinical Laboratory Association and its member company, HealthTrackRx, filed a lawsuit today against the U.S. Food and Drug Administration in the U.S. District Court for the Eastern District of Texas, challenging the agency’s May 6 final rule, which seeks to regulate professional laboratory testing services as medical devices under the Federal Food, Drug, and Cosmetic Act.
May 28, 2024—BioMérieux received FDA 510(k) clearance for its Vidas TBI (GFAP, UCH-L1), a serum-based test that supports the assessment of patients with mild traumatic brain injury, including concussion.
May 22, 2024—Roche announced that the Tina-quant lipoprotein Lp(a) RxDx assay, developed in collaboration with Amgen, has received breakthrough device designation from the FDA.
May 20, 2024—Amgen announced FDA approval of Imdelltra (tarlatamab-dlle) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.
May 17, 2024—Diasorin received FDA 510(k) clearance for its NxTag Respiratory Pathogen Panel v2.
May 16, 2024—BD announced FDA approval of the BD Onclarity HPV assay for the use of self-collected vaginal specimens for HPV testing when cervical specimens cannot otherwise be obtained.
May 15, 2024—The FDA has approved Roche’s HPV self-collection solution for use with the company’s Cobas HPV test.
May 13, 2024—Qiagen announced that the FDA has cleared its QIAstat-Dx Respiratory Panel Plus syndromic test for clinical use.
May 8, 2024—Indica Labs received FDA 510(k) clearance for its Halo AP Dx digital pathology platform for use in primary diagnosis.
